World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 86 14018 13199 583 556 680 30395

Vikas Gupta publications per year

The chart shows the history of publications by Vikas Gupta between 2000 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Vikas Gupta published across 26 years, from 2000 to 2025, averaging 36.3 papers a year. Output peaked at 108 publications in 2022. 92 of the 944 publications appeared in the last two years.

No. of publications
25 50 75 100
Bar chart. Horizontal axis: year, 2000 to 2025. Vertical axis: number of publications, 0 to 108. Peak 108 publications in 2022. 2000: 1 publication 2001: 4 publications 2002: 1 publication 2003: 8 publications 2004: 11 publications 2005: 14 publications 2006: 14 publications 2007: 23 publications 2008: 24 publications 2009: 29 publications 2010: 28 publications 2011: 27 publications 2012: 48 publications 2013: 52 publications 2014: 54 publications 2015: 47 publications 2016: 45 publications 2017: 46 publications 2018: 39 publications 2019: 47 publications 2020: 47 publications 2021: 54 publications 2022: 108 publications 2023: 81 publications 2024: 61 publications 2025: 31 publications
2000 2025

944 publications in total across all disciplines

View publications per year as a table
Vikas Gupta: publications per year, 2000 to 2025
Year Publications
2000 1
2001 4
2002 1
2003 8
2004 11
2005 14
2006 14
2007 23
2008 24
2009 29
2010 28
2011 27
2012 48
2013 52
2014 54
2015 47
2016 45
2017 46
2018 39
2019 47
2020 47
2021 54
2022 108
2023 81
2024 61
2025 31
Total 944
Download as CSV

Vikas Gupta publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Vikas Gupta sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 661–680 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 680 publications — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340 680
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Vikas Gupta D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Vikas Gupta sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 86–87 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960 86
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Vikas Gupta is affiliated with the Princess Margaret Cancer Centre in Canada. Their research primarily focuses on medical studies related to hematology and related subfields.

The scientist's main field of study is Medicine, with a specialized emphasis on Hematology, Genetics, Molecular Biology, Rheumatology, and Surgery. Their published work spans across multiple prominent medical topics, including:

  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Acute Myeloid Leukemia Research
  • Eosinophilic Disorders and Syndromes
  • Kruppel-like factors research
  • Multiple Myeloma Research and Treatments
  • Acute Lymphoblastic Leukemia research

Some of the recent notable papers authored or co-authored by them include:

  • "Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study," 2023, The Lancet
  • "ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial," 2020, Blood Advances
  • "Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts," 2020, British Journal of Haematology
  • "Survival following allogeneic transplant in patients with myelofibrosis," 2020, Blood Advances
  • "Critical illness in patients with hematologic malignancy: a population-based cohort study," 2021, Intensive Care Medicine

Vikas Gupta frequently collaborates with other researchers in their field. The most common co-authors include:

  • Ruben A. Mesa
  • Srđan Verstovšek
  • Hassan Sibai
  • Jean-Jacques Kiladjian
  • Dawn Maze

They have published across several key journals and platforms, notably:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Blood Advances
  • HemaSphere
  • Journal of Clinical Oncology

Best Publications

  • A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

    Srdan Verstovsek;Ruben A. Mesa;Jason Gotlib;Richard S. Levy

  • Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia

    Liran I. Shlush;Sasan Zandi;Amanda Mitchell;Weihsu Claire Chen

  • Epidemiology and Outcomes of Health-care–Associated Pneumonia: Results From a Large US Database of Culture-Positive Pneumonia

    Marin H. Kollef;Andrew Shorr;Ying P. Tabak;Vikas Gupta

  • A 17-gene stemness score for rapid determination of risk in acute leukaemia

    Stanley W. K. Ng;Amanda Mitchell;James A. Kennedy;James A. Kennedy;James A. Kennedy;Weihsu C. Chen

  • Risk factors for acute GVHD and survival after hematopoietic cell transplantation.

    Madan Jagasia;Mukta Arora;Mary E D Flowers;Nelson J. Chao

  • Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome

    Brian L. McClune;Daniel J. Weisdorf;Tanya L. Pedersen;Gisela Tunes da Silva

  • Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure

    Michel Duval;John P. Klein;Wensheng He;Jean Yves Cahn

  • The Nf2 Tumor Suppressor, Merlin, Functions in Rac-Dependent Signaling

    Reuben J. Shaw;J.Guillermo Paez;Marcello Curto;Ann Yaktine

  • Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database.

    Andrew F. Shorr;Ying P. Tabak;Aaron D. Killian;Vikas Gupta

  • Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.

    Srdan Verstovsek;Ruben A Mesa;Jason R Gotlib;Vikas Gupta

  • OUTCOME OF TRANSPLANTATION FOR MYELOFIBROSIS

    Karen K. Ballen;Smriti Shrestha;Kathleen A. Sobocinski;Mei Jie Zhang

  • Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.

    N. M. Kröger;J. H. Deeg;E. Olavarria;D. Niederwieser

  • Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial

    John Mascarenhas;Ronald Hoffman;Moshe Talpaz;Aaron T. Gerds

  • Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation

    Joseph Pidala;Stephanie J. Lee;Kwang Woo Ahn;Stephen Spellman

  • Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: Results of a median 3-year follow-up of COMFORT-I

    Srdan Verstovsek;Ruben A. Mesa;Jason Gotlib;Richard S. Levy

  • Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.

    Selina M. Luger;Olle Ringdén;Mei-Jie Zhang;Waleska S. Pérez

  • Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.

    Claire N. Harrison;Alessandro M. Vannucchi;Uwe Platzbecker;Francisco Cervantes

  • Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.

    Srdan Verstovsek;Jason Gotlib;Ruben A. Mesa;Alessandro M. Vannucchi

  • Corrigendum: Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia

    Liran I. Shlush;Sasan Zandi;Amanda Mitchell;Weihsu Claire Chen

Frequent Co-Authors

Mark D. Minden
Mark D. Minden Princess Margaret Cancer Centre
Aaron D. Schimmer
Aaron D. Schimmer Princess Margaret Cancer Centre
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Ruben A. Mesa
Ruben A. Mesa The University of Texas Health Science Center at San Antonio
Sagar Lonial
Sagar Lonial Emory University
Lawrence H. Boise
Lawrence H. Boise Emory University
Suzanne Kamel-Reid
Suzanne Kamel-Reid University Health Network
Jason Gotlib
Jason Gotlib Stanford University
Moshe Talpaz
Moshe Talpaz University of Michigan–Ann Arbor
Wei Xu
Wei Xu Shenzhen University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine doesn’t have to follow a single track. Many students explore alternative pathways and online degree options to broaden their opportunities in healthcare. For those seeking quicker entry into the workforce, fast lpn program options can fast-track your path to becoming a Licensed Practical Nurse, offering flexible schedules and faster completion times.

Mental health is a rapidly growing field, and online study options are making it more accessible than ever. If you’re interested in advanced practice, you may want to consider online psych np programs to become a Psychiatric Mental Health Nurse Practitioner. These programs blend flexibility and specialization, letting you build expertise in high-demand areas.

For students interested in the organizational side of healthcare, pursuing a Master’s in Healthcare Administration (MHA) opens up leadership and management roles. Affordable and accessible cheapest mha programs online provide a budget-friendly alternative to traditional campus options. You can also compare different cheapest mha programs online to find the best fit for your career goals and financial needs.

Best Scientists Citing Vikas Gupta

Trending Scientists

Recently Published Articles